US Patent Issued to Curium US on Oct. 6 for "Radiopharmaceutical compositions for actinium in targeted radionuclide therapy" (Finnish Inventors)

ALEXANDRIA, Va., Oct. 6 -- United States Patent no. 12,752,026, issued on Oct. 6, was assigned to Curium US LLC (St. Louis).

"Radiopharmaceutical compositions for actinium in targeted radionuclide therapy" was invented by Jarno Jalomaki (Helsinki), Salla Seppanen (Helsinki) and Riku Parviainen (Helsinki).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides a high-energy, low toxicity radiopharmaceutical composition comprising actinium that performs as an anti-tumor agent for targeted radionuclide therapy and has improved shelf-life stability. Specifically, the radiopharmaceutical composition may include 225Ac-PSMA I&T, sodium ascorbate, and optionally hydrochloric acid. The radiophar...